Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dacomitinib Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 19/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 13/20 | 1.00 |
| ▸ | ERBB4 known ✓ | Q15303 | 8/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | MC3R | P41968 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dacomitinib Anhydrous SCHEMBL33147 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29354322 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL30115337 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29377735 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29396914 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL25098 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL33136 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL22498351 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29445648 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29359689 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193274-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | PRINCIPIA BIOPHARMA INC. | 2018-07-12 | — | — | US | claimed |
| EP-1746999-B1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER LAMBERT CO (US) | 2011-11-16 | — | — | EP | claimed |
| US-20110262877-A1 | HEAT TREATMENT APPARATUS | IHI CORPORATION (JP) | 2011-10-27 | — | — | US | claimed |
| EP-4706656-A1 | COMBINATION THERAPY OF DACOMITINIB AND NINTEDANIB FOR PREVENTION OR TREATMENT OF PULMONARY FIBROSIS | Korea Institute of Radiological & Medical Sciences (KR) | 2026-03-11 | — | — | EP | disclosed |
| EP-4707275-A1 | NOVEL COMPOUND COMPRISING N-METHYLPIPERAZINE ETHANOL CARBAMATE STRUCTURE AND USE THEREOF | Korea Institute of Radiological & Medical Sciences (KR) | 2026-03-11 | — | — | EP | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-12378302-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2024225819-A1 | NOVEL COMPOUND COMPRISING N-METHYLPIPERAZINE ETHANOL CARBAMATE STRUCTURE AND USE THEREOF | 한국원자력의학원 | 2024-10-31 | — | — | WO | disclosed |
| WO-2024225820-A1 | COMBINATION THERAPY OF DACOMITINIB AND NINTEDANIB FOR PREVENTION OR TREATMENT OF PULMONARY FIBROSIS | 한국원자력의학원 | 2024-10-31 | — | — | WO | disclosed |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| US-20180193274-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | PRINCIPIA BIOPHARMA INC. | 2018-07-12 | — | — | US | disclosed |
| EP-3236943-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | PRINCIPIA BIOPHARMA INC. (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016105582-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | NUNN PHILIP A (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20150160246-A1 | DEVICES AND METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | ANALIZA, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| EP-1746999-B1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER LAMBERT CO (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262877-A1 | HEAT TREATMENT APPARATUS | IHI CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-1746999-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | Warner-Lambert Company LLC (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005107758-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193274-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | BTK, LCK, DSTYK | EGFR 228/4885ERBB2 52/4885ERBB4 349/4885 |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | EGFR 2414/4885ERBB2 1580/4885ERBB4 1681/4885 |
| US-12378302-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | EGFR 2095/4885ERBB2 1560/4885ERBB4 1596/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | EGFR 2414/4885ERBB2 1580/4885ERBB4 1681/4885 |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | EGFR 2414/4885ERBB2 1580/4885ERBB4 1681/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | EGFR 2095/4885ERBB2 1560/4885ERBB4 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.